Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement…
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of…
MUMBAI, India, May 29, 2025 /PRNewswire/ -- Suraj Estate Developers Ltd. today announced its financial results for the fiscal year…
NEW YORK--(BUSINESS WIRE)--#creditratingagency--KBRA assigns an issuer rating of BBB to The Fortegra Group, Inc. (TFG or Fortegra) and assigns an…